Amunix Raises $117m To Take Novel T-Cell Engager Into The Clinic
Technology Out-Licensor Has Transitioned To Drug Developer
Amunix’s XTEN technology for half-life extension and precise drug delivery has been used by multiple partners over the past 15 years, but now the firm is building its own cancer therapy pipeline.
